SCHEMBL1169982

SCHEMBL1169982

Fc1ccc(CNc2nc3ccccc3n2Cc2ccc(F)cc2)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.69
MAPT P10636 1/20 0.69
SMN1; SMN2 Q16637 3/20 0.61
KCNH2 Q12809 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 2/20 0.61
CYP2D6 P10635 2/20 0.61
CYP2C19 P33261 2/20 0.61
CYP2C9 P11712 1/20 0.61
NR4A2 P43354 1/20 0.61
RAB9A P51151 3/20 0.60
TRPC5 Q9UL62 2/20 0.60
TRPC4 Q9UBN4 1/20 0.60
LMNA P02545 4/20 0.59
SSTR5 P35346 1/20 0.59
DRD2 P14416 1/20 0.59
TBXA2R P21731 1/20 0.59
HTT P42858 2/20 0.57
NPC1 O15118 2/20 0.57
KMT2A Q03164 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170660 0.88 ALDH1A1 (0.86) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL1170123 0.87 SMN1; SMN2 (0.74) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL14263846 0.87 KCNH2 (0.62) ALDH1A1MAPTSMN1; SMN2KCNH2CYP1A2
SCHEMBL13351525 0.86 RAB9A (0.64) MAPTSMN1; SMN2KCNH2CYP1A2CYP2D6
SCHEMBL1170647 0.84 SMN1; SMN2 (0.60) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL8223395 0.82 RAB9A (0.60) KCNH2CYP1A2CYP2D6CYP2C19CYP2C9
SCHEMBL1170118 0.81 KMT2A (0.64) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL10032040 0.80 KMT2A (0.68) ALDH1A1MAPTSMN1; SMN2LMNAHTT
SCHEMBL1169930 0.79 SMN1; SMN2 (0.66) ALDH1A1MAPTSMN1; SMN2CYP1A2CYP3A4
SCHEMBL8912625 0.79 SSTR5 (0.58) MAPTSMN1; SMN2KCNH2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2319512-A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. NeuroSearch AS (DK) 2011-05-11 EP claimed
US-20110034527-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS SOERENSEN ULRIK SVANE 2011-02-10 US claimed
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels NEURO SEARCH A/S (DK) 2008-08-21 US claimed
EP-2319512-A1 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels. NeuroSearch AS (DK) 2011-05-11 EP disclosed
US-20110034527-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS SOERENSEN ULRIK SVANE 2011-02-10 US disclosed
US-7842817-B2 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels NEUROSEARCH A/S (DK) 2010-11-30 US disclosed
EP-1838306-B1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS NEUROSEARCH AS (DK) 2010-11-17 EP disclosed
US-20100280087-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS SOERENSEN ULRIK SVANE 2010-11-04 US disclosed
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels NEURO SEARCH A/S (DK) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034527-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 ALDH1A1 3979/4885MAPT 1733/4885SMN1; SMN2 2965/4885
US-20080200529-A1 Novel 2-Amino Benzimidazole Derivatives and Their Use As Modulators Of Small-Conductance Calcium-Activated Potassium Channels KCNN2, KCNN1, KCNN3 ALDH1A1 3979/4885MAPT 1733/4885SMN1; SMN2 2965/4885
US-20100280087-A1 NOVEL 2-AMINO BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS KCNN2, KCNN1, KCNN3 ALDH1A1 3979/4885MAPT 1733/4885SMN1; SMN2 2965/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.